Search

Your search keyword '"Ercole, Cesar E."' showing total 39 results
Start Over Author "Ercole, Cesar E."
39 results on '"Ercole, Cesar E."'

1. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer

Author

D’Andrea, David, Black, Peter C., Zargar, Homayoun, Zargar-Shoshtari, Kamran, Soria, Francesco, Fairey, Adrian S., Mertens, Laura S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Campain, Nicholas J., Kassouf, Wassim, Dall’Era, Marc A., Seah, Jo-An, Ercole, Cesar E., Horenblas, Simon, Sridhar, Srikala S., McGrath, John S., Aning, Jonathan, Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Grivas, Petros, Stephenson, Andrew J., Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., and Shariat, Shahrokh F.

Published
2021
Full Text
View/download PDF

2. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy

Author

Fransen van de Putte, Elisabeth E., Horenblas, Simon, Potvin, Kylea R., Winquist, Eric, Seah, Jo-An, Sridhar, Srikala S., Jacobsen, Niels-Erik, Zargar-Shoshtari, Kamran, Holzbeierlein, Jeff M., Griffin, Joshua, Dinney, Colin, Krabbe, Laura-Maria, Lotan, Yair, Kovac, Evan, Ercole, Cesar E., Stephenson, Andrew J., Grivas, Petros, Cookson, Michael S., Baras, Alex, Montgomery, Jeffrey S., Morgan, Todd M., Vasdev, Nikhil, Thorpe, Andrew C., Campain, Nicholas J., McGrath, John S., Yu, Evan Y., Wright, Jonathan L., Xylinas, Evanguelos, Dall'Era, Marc A., Barocas, Daniel A., Fairey, Adrian S., Shariat, Shahrokh F., Aning, Jonathan, Zargar, Homayoun, Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Bivalacqua, Trinity J., Spiess, Philippe E., Black, Peter C., and Kassouf, Wassim

Published
2018
Full Text
View/download PDF

5. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease

Author

Awasthi, Shivanshu, primary, Grass, G Daniel, additional, Torres-Roca, Javier, additional, Johnstone, Peter A S, additional, Pow-Sang, Julio, additional, Dhillon, Jasreman, additional, Park, Jong, additional, Rounbehler, Robert J, additional, Davicioni, Elai, additional, Hakansson, Alex, additional, Liu, Yang, additional, Fink, Angelina K, additional, DeRenzis, Amanda, additional, Creed, Jordan H, additional, Poch, Michael, additional, Li, Roger, additional, Manley, Brandon, additional, Fernandez, Daniel, additional, Naghavi, Arash, additional, Gage, Kenneth, additional, Lu-Yao, Grace, additional, Katsoulakis, Evangelia, additional, Burri, Ryan J, additional, Leone, Andrew, additional, Ercole, Cesar E, additional, Palmer, Joshua D, additional, Vapiwala, Neha, additional, Deville, Curtiland, additional, Rebbeck, Timothy R, additional, Dicker, Adam P, additional, Kelly, William, additional, and Yamoah, Kosj, additional

Published
2022
Full Text
View/download PDF

8. Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study

Author

Fink, Angelina K. C., primary, DeRenzis, Amanda C., additional, Awasthi, Shivanshu, additional, Jahan, Nawreen, additional, Johnstone, Peter A. S., additional, Pow‐Sang, Julio, additional, Torres‐Roca, Javier, additional, Grass, Daniel, additional, Fernandez, Daniel, additional, Naghavi, Arash, additional, Tan, Susan, additional, Manley, Brandon, additional, Li, Roger, additional, Poch, Michael, additional, Yu, Alice, additional, Little, Nikki, additional, Bass, Eppie, additional, Ercole, Cesar E., additional, Katsoulakis, Evangelia, additional, Burri, Ryan, additional, Smith, Riley, additional, Stanley, Nathanael B., additional, Vadaparampil, Susan T., additional, and Yamoah, Kosj, additional

Published
2022
Full Text
View/download PDF

10. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease

Author

Awasthi, Shivanshu, Grass, G. Daniel, Torres-Roca, Javier, Johnstone, Peter A. S., Pow-Sang, Julio, Dhillon, Jasreman, Park, Jong, Rounbehler, Robert J., Davicioni, Elai, Hakansson, Alex, Liu, Yang, Fink, Angelina K., DeRenzis, Amanda, Creed, Jordan H., Poch, Michael, Li, Roger, Manley, Brandon, Fernandez, Daniel, Naghavi, Arash, Gage, Kenneth, Lu-Yao, Grace, Katsoulakis, Evangelia, Burri, Ryan J., Leone, Andrew, Ercole, Cesar E., Palmer, Joshua D., Vapiwala, Neha, Deville, Curtiland, Rebbeck, Timothy R., Dicker, Adam P., Kelly, William, Yamoah, Kosj, Awasthi, Shivanshu, Grass, G. Daniel, Torres-Roca, Javier, Johnstone, Peter A. S., Pow-Sang, Julio, Dhillon, Jasreman, Park, Jong, Rounbehler, Robert J., Davicioni, Elai, Hakansson, Alex, Liu, Yang, Fink, Angelina K., DeRenzis, Amanda, Creed, Jordan H., Poch, Michael, Li, Roger, Manley, Brandon, Fernandez, Daniel, Naghavi, Arash, Gage, Kenneth, Lu-Yao, Grace, Katsoulakis, Evangelia, Burri, Ryan J., Leone, Andrew, Ercole, Cesar E., Palmer, Joshua D., Vapiwala, Neha, Deville, Curtiland, Rebbeck, Timothy R., Dicker, Adam P., Kelly, William, and Yamoah, Kosj

Abstract

BACKGROUND: Personalized genomic classifiers have transformed the management of prostate cancer (PCa) by identifying the most aggressive subsets of PCa. Nevertheless, the performance of genomic classifiers to risk classify African American men is thus far lacking in a prospective setting. METHODS: This is a prospective study of the Decipher genomic classifier for National Comprehensive Cancer Network low- and intermediate-risk PCa. Study-eligible non-African American men were matched to African American men. Diagnostic biopsy specimens were processed to estimate Decipher scores. Samples accrued in NCT02723734, a prospective study, were interrogated to determine the genomic risk of reclassification (GrR) between conventional clinical risk classifiers and the Decipher score. RESULTS: The final analysis included a clinically balanced cohort of 226 patients with complete genomic information (113 African American men and 113 non-African American men). A higher proportion of African American men with National Comprehensive Cancer Network-classified low-risk (18.2%) and favorable intermediate-risk (37.8%) PCa had a higher Decipher score than non-African American men. Self-identified African American men were twice more likely than non-African American men to experience GrR (relative risk [RR] = 2.23, 95% confidence interval [CI] = 1.02 to 4.90; P = .04). In an ancestry-determined race model, we consistently validated a higher risk of reclassification in African American men (RR = 5.26, 95% CI = 1.66 to 16.63; P = .004). Race-stratified analysis of GrR vs non-GrR tumors also revealed molecular differences in these tumor subtypes. CONCLUSIONS: Integration of genomic classifiers with clinically based risk classification can help identify the subset of African American men with localized PCa who harbor high genomic risk of early metastatic disease. It is vital to identify and appropriately risk stratify the subset of African American men with aggressive disease who may benefit

Published
2022

12. List of Contributors

Author

Abbosh, Philip H., primary, Abdollah, Firas, additional, Achary, Mohan P., additional, Alanee, Shaheen, additional, Albertsen, Peter C., additional, Al-Shraideh, Yousef, additional, Andriole, Gerald, additional, Baack Kukreja, Janet E., additional, Babayan, Richard K., additional, Baker, Brock R., additional, Bayne, Christopher E., additional, Bilusic, Marijo, additional, Bokhorst, Leonard P., additional, Cahn, David B., additional, Canter, Daniel J., additional, Chen, David Y.T., additional, Chen, Ronald C., additional, Chipollini, Juan, additional, Choyke, Peter L., additional, Cooperberg, Matthew R., additional, Costello, Anthony, additional, Crawford, E. David, additional, Deville, Curtiland, additional, Dulaimi, Essel, additional, Dynda, Danuta, additional, Eifler, John B., additional, Ercole, Cesar E., additional, Eun, Daniel D., additional, Everaerts, Wouter, additional, Faiena, Izak, additional, Ferragamo, Michael A., additional, Flack, Chandra K., additional, Garg, Tullika, additional, Gherezghihir, Awet, additional, Godec, Ciril J., additional, Gomella, Leonard G., additional, Greenberg, Richard E., additional, Grob, Baruch Mayer, additional, Guazzoni, Giorgio, additional, Guzzo, Thomas J., additional, Haddad, Ahmed, additional, Haider, Maahum, additional, Harbin, Andrew C., additional, Horwitz, Eric M., additional, Hussein, Ahmed A., additional, Ito, Timothy, additional, Jarrett, Thomas W., additional, Jenkins, Lawrence C., additional, Kaplan, Joshua R., additional, Katz, Mark H., additional, Kavoussi, Louis R., additional, Kiechle, Jonathan, additional, Kim, Simon P., additional, Klotz, Laurence, additional, Koch, Michael O., additional, Kundavaram, Chandan, additional, Kutikov, Alexander, additional, Lallas, Costas D., additional, Lange, Paul H., additional, Lazzeri, Massimo, additional, Lin, Daniel W., additional, Lotan, Yair, additional, Lythgoe, Casey, additional, Makarov, Danil V., additional, Mann, Mark, additional, Marcus, David M., additional, Master, Viraj A., additional, Meeks, Joshua J., additional, Mendhiratta, Neil, additional, Menon, Mani, additional, Messing, Edward M., additional, Miyamoto, Curtis T., additional, Modi, Parth K., additional, Mohiuddin, Jahan J., additional, Monn, M. Francesca, additional, Montorsi, Francesco, additional, Moon, Daniel, additional, Moses, Kelvin A., additional, Moul, Judd W., additional, Moyad, Mark A., additional, Mucksavage, Phillip, additional, Mulhall, John P., additional, Murphy, Declan G., additional, Mydlo, Jack H., additional, Nelson, Joel B., additional, Parihar, Jaspreet Singh, additional, Parker, Daniel C., additional, Parrillo, Lisa, additional, Patel, Neal, additional, Pavlovich, Christian P., additional, Petrossian, Albert, additional, Pietzak, Eugene, additional, Pinto, Peter, additional, Piotrowski, Zachary, additional, Pontari, Michel A., additional, Punnen, Sanoj, additional, Raman, Jay D., additional, Reese, Adam C., additional, Reeves, Fairleigh, additional, Rij, Simon Van, additional, Ristau, Benjamin T., additional, Roobol, Monique J., additional, Salami, Simpa S., additional, Salmasi, Amirali H., additional, Sankineni, Sandeep, additional, Scarpato, Kristen R., additional, Schade, George R., additional, Schaff, Matthew S., additional, Sejpal, Samir V., additional, Shore, Neal D., additional, Simhan, Jay, additional, Slovin, Susan F., additional, Smaldone, Marc C., additional, Smith, Joseph A., additional, Stephenson, Andrew J., additional, Steyerberg, Ewout W., additional, Stimson, C.J., additional, Sutcliffe, Siobhan, additional, Taneja, Samir S., additional, Tang, Vincent, additional, Tausch, Timothy J., additional, Thrasher, James Brantley, additional, Torre, Taryn G., additional, Trabulsi, Edouard J., additional, Turkbey, Baris, additional, Turner, Robert M., additional, Underwood, Willie, additional, Vemana, Goutham, additional, Venkatachalam, Shilpa, additional, Ventii, Karen H., additional, Wein, Alan, additional, Wright, Jonathan L., additional, Wyre, Hadley, additional, Yi Kim, Isaac, additional, Young, Melissa R., additional, Yu, James B., additional, and Zaorsky, Nicholas G., additional

Published
2016
Full Text
View/download PDF

13. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?

Author

Zargar, Homayoun, Zargar-Shoshtari, Kamran, Lotan, Yair, Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., Black, Peter, Fairey, Adrian S., Mertens, Laura S., Horenblas, Simon, Dinney, Colin P., Mir, Maria C., Ercole, Cesar E., Stephenson, Andrew J., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Barocas, Daniel A., Griffin, Joshua, Holzbeierlein, Jeff M., Montgomery, Jeffrey S., Morgan, Todd M., Vasdev, Nikhil, Thorpe, Andrew C., Aning, Jonathan, Yu, Evan Y., Wright, Jonathan L., Xylinas, Evanguelos, Campain, Nicholas J., Pourmalek, Farshad, McGrath, John S., Kassouf, Wassim, DallʼEra, Marc A., Seah, Jo-An, Sridhar, Srikala S., Sharma, Pranav, Shariat, Shahrokh F., North, Scott, Grivas, Petros, Gandhi, Nilay, and Bivalacqua, Trinity J.

Published
2016
Full Text
View/download PDF

14. Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study.

Author

Fink, Angelina K. C., DeRenzis, Amanda C., Awasthi, Shivanshu, Jahan, Nawreen, Johnstone, Peter A. S., Pow‐Sang, Julio, Torres‐Roca, Javier, Grass, Daniel, Fernandez, Daniel, Naghavi, Arash, Tan, Susan, Manley, Brandon, Li, Roger, Poch, Michael, Yu, Alice, Little, Nikki, Bass, Eppie, Ercole, Cesar E., Katsoulakis, Evangelia, and Burri, Ryan

Subjects
CLINICAL trials, AFRICAN American men, PARTICIPATION, CANCER research
Abstract

Participation in cancer research trials by minority populations is imperative in reducing disparities in clinical outcomes. Even with increased awareness of the importance of minority patient inclusion in clinical research to improve cancer care and survival, significant barriers persist in accruing and retaining minority patients into clinical trials. This study sought to identify and address barriers to minority accrual to a minimal risk clinical research study in real‐time. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. PD41-05 FINAL PATHOLOGIC STAGE AFTER NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR BLADDER CANCER: DOES PT0 PREDICT BETTER SURVIVAL THAN PTA/PTIS/PT1?

Author

Zargar, Homayoun, Zargar-Shoshtari, Kamran, Fairey, Adrian S., Mertens, Laura S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Gandhi, Nilay, Griffin, Joshua, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Campain, Nicholas J., Kassouf, Wassim, DallʼEra, Marc A., Seah, Jo-An, Ercole, Cesar E., Horenblas, Simon, Sridhar, Srikala S., McGrath, John S., Aning, Jonathan, Shariat, Shahrokh F., Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Garcia, Jorge A., Stephenson, Andrew J., Shah, Jay B., Van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., and Black, Peter C.

Published
2015
Full Text
View/download PDF

16. MP65-06 A MULTI-INSTITUTIONAL ANALYSIS OF OUTCOMES IN PATIENTS WITH CLINICALLY NODE POSITIVE UROTHELIAL BLADDER CANCER TREATED WITH INDUCTION CHEMOTHERAPY AND RADICAL CYSTECTOMY

Author

Zargar-Shoshtari, Kamran, Zargar, Homayoun, Fairey, Adrian S., Mertens, Laura S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Gandhi, Nilay, Griffin, Joshua, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Campain, Nicholas J., Kassouf, Wassim, DallʼEra, Marc A., Seah, Jo-An, Sharma, Pranav, Ercole, Cesar E., Horenblas, Simon, Sridhar, Srikala S., McGrath, John S., Aning, Jonathan, Shariat, Shahrokh F., Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Garcia, Jorge A., Stephenson, Andrew J., Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., and Black, Peter

Published
2015
Full Text
View/download PDF

18. A prospective validation of the genomic classifier to define high-metastasis risk in a subset of African American men with early localized prostate cancer: VanDAAM study.

Author

Yamoah, Kosj, primary, Dhillon, Jasreman, additional, Johnstone, Peter A., additional, Pow-Sang, Julio M., additional, Davicioni, Elai, additional, Fink, Angelina, additional, DeRenzis, Amanda C, additional, Grass, G. Daniel, additional, Li, Roger, additional, Manley, Brandon J, additional, Gage, Kenneth L., additional, Katsoulakis, Evangelia, additional, Burri, Ryan J, additional, Leone, Andrew, additional, Ercole, Cesar E, additional, Palmer, Joshua David, additional, Vapiwala, Neha, additional, Deville, Curtiland, additional, Rebbeck, Timothy, additional, and Dicker, Adam P., additional

Published
2021
Full Text
View/download PDF

20. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer

Author

D'Andrea, David, primary, Black, Peter C., additional, Zargar, Homayoun, additional, Zargar-Shoshtari, Kamran, additional, Zehetmayer, Sonja, additional, Fairey, Adrian S., additional, Mertens, Laura S., additional, Dinney, Colin P., additional, Mir, Maria C., additional, Krabbe, Laura-Maria, additional, Cookson, Michael S., additional, Jacobsen, Niels-Erik, additional, Montgomery, Jeffrey S., additional, Vasdev, Nikhil, additional, Yu, Evan Y., additional, Xylinas, Evanguelos, additional, Campain, Nicholas J., additional, Kassouf, Wassim, additional, Dall'Era, Marc A., additional, Seah, Jo-An, additional, Ercole, Cesar E., additional, Horenblas, Simon, additional, Sridhar, Srikala S., additional, McGrath, John S., additional, Aning, Jonathan, additional, Wright, Jonathan L., additional, Thorpe, Andrew C., additional, Morgan, Todd M., additional, Holzbeierlein, Jeffrey M., additional, Bivalacqua, Trinity J., additional, North, Scott, additional, Barocas, Daniel A., additional, Lotan, Yair, additional, Grivas, Petros, additional, Stephenson, Andrew J., additional, Shah, Jay B., additional, van Rhijn, Bas W., additional, Daneshmand, Siamak, additional, Spiess, Philippe E., additional, and Shariat, Shahrokh F., additional

Published
2020
Full Text
View/download PDF

21. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy

Author

Black, Anna J., primary, Zargar, Homayoun, additional, Zargar-Shoshtari, Kamran, additional, Fairey, Adrian S., additional, Mertens, Laura S., additional, Dinney, Colin P., additional, Mir, Maria C., additional, Krabbe, Laura-Maria, additional, Cookson, Michael S., additional, Jacobsen, Niels-Erik, additional, Griffin, Joshua, additional, Montgomery, Jeffrey S., additional, Vasdev, Nikhil, additional, Yu, Evan Y., additional, Xylinas, Evanguelos, additional, Campain, Nicholas J., additional, Kassouf, Wassim, additional, Dall'Era, Marc A., additional, Seah, Jo-An, additional, Ercole, Cesar E., additional, Horenblas, Simon, additional, McGrath, John S., additional, Aning, Jonathan, additional, Shariat, Shahrokh F., additional, Wright, Jonathan L., additional, Thorpe, Andrew C., additional, Morgan, Todd M., additional, Holzbeierlein, Jeff M., additional, Bivalacqua, Trinity J., additional, North, Scott, additional, Barocas, Daniel A., additional, Lotan, Yair, additional, Grivas, Petros, additional, Stephenson, Andrew J., additional, Shah, Jay B., additional, van Rhijn, Bas W., additional, Spiess, Philippe E., additional, Daneshmand, Siamak, additional, Sridhar, Srikala S., additional, and Black, Peter C., additional

Published
2020
Full Text
View/download PDF

23. MP58-04 DENSE DOSE MVAC VERSUS GC IN PATIENTS WITH CT3-4A BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: A REAL WORLD EXPERIENCE

Author

Zargar, Homayoun, primary, Shah, Jay B, additional, van de Putte, Elisabeth E Fransen, additional, Potvin, Kylea R., additional, Zargar-Shoshtari, Kamran, additional, van Rhijn, Bas W, additional, Daneshmand, Siamak, additional, Holzbeierlein, Jeff M, additional, Spiess, Philippe E, additional, Winquist, Eric, additional, Horenblas, Simon, additional, Dinney, Colin, additional, Fairey, Adrian S, additional, Kovac, Evan, additional, Krabbe, Laura-Maria, additional, Cookson, Michael S, additional, Jacobsen, Niels-Erik, additional, Gandhi, Nilay, additional, Griffin, Joshua, additional, Montgomery, Jeffrey S, additional, Vasdev, Nikhil, additional, Yu, Evan Y, additional, Xylinas, Evanguelos, additional, Campain, Nicholas J., additional, Seah, Jo-An, additional, Ercole, Cesar E, additional, Sridhar, Srikala S, additional, McGrath, John S, additional, Aning, Jonathan, additional, Shariat, Shahrokh F, additional, Wright, Jonathan L, additional, Thorpe, Andrew C, additional, Morgan, Todd M, additional, Grivas, Petros, additional, Stephenson, Andrew J, additional, Bivalacqua, Trinity J, additional, North, Scott, additional, Barocas, Daniel A, additional, Lotan, Yair, additional, Black, Peter C, additional, and Kassouf, Wassim, additional

Published
2017
Full Text
View/download PDF

26. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy

Author

Zargar-Shoshtari, Kamran, primary, Zargar, Homayoun, additional, Dinney, Colin P., additional, Ercole, Cesar E., additional, Sharma, Pranav, additional, Kovac, Evan, additional, Grivas, Petros D., additional, Stephenson, Andrew J., additional, Shah, Jay B., additional, Black, Peter C., additional, and Spiess, Philippe E., additional

Published
2015
Full Text
View/download PDF

29. Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Author

Zargar, Homayoun, primary, Espiritu, Patrick N., additional, Fairey, Adrian S., additional, Mertens, Laura S., additional, Dinney, Colin P., additional, Mir, Maria C., additional, Krabbe, Laura-Maria, additional, Cookson, Michael S., additional, Jacobsen, Niels-Erik, additional, Gandhi, Nilay M., additional, Griffin, Joshua, additional, Montgomery, Jeffrey S., additional, Vasdev, Nikhil, additional, Yu, Evan Y., additional, Youssef, David, additional, Xylinas, Evanguelos, additional, Campain, Nicholas J., additional, Kassouf, Wassim, additional, Dall’Era, Marc A., additional, Seah, Jo-An, additional, Ercole, Cesar E., additional, Horenblas, Simon, additional, Sridhar, Srikala S., additional, McGrath, John S., additional, Aning, Jonathan, additional, Shariat, Shahrokh F., additional, Wright, Jonathan L., additional, Thorpe, Andrew C., additional, Morgan, Todd M., additional, Holzbeierlein, Jeff M., additional, Bivalacqua, Trinity J., additional, North, Scott, additional, Barocas, Daniel A., additional, Lotan, Yair, additional, Garcia, Jorge A., additional, Stephenson, Andrew J., additional, Shah, Jay B., additional, van Rhijn, Bas W., additional, Daneshmand, Siamak, additional, Spiess, Philippe E., additional, and Black, Peter C., additional

Published
2015
Full Text
View/download PDF

32. Current Concepts in Penile Cancer

Author

Spiess, Philippe E., primary, Horenblas, Simon, additional, Pagliaro, Lance C., additional, Biagioli, Matthew C., additional, Crook, Juanita, additional, Clark, Peter E., additional, Greenberg, Richard E., additional, and Ercole, Cesar E., additional

Published
2013
Full Text
View/download PDF

36. Robot assisted laparoscopic retroperitoneal lymph node dissection in testicular tumor.

Author

Ercole, Cesar E., Mir, Maria Carmen, Autorino, Riccardo, and Kaouk, Jihad H.

Subjects
*MEDICAL robotics, TESTIS surgery
Abstract

A letter to the editor is presented in response to the article "Robot assisted laparoscopic retroperitoneal lymph node dissection in testical tumor" by P. N. Dogra, P. Singh, B. G. Singh and B. Nayak which describes the clinical stage of non-seminomatous germ cell testicular.

Published
2014
Full Text
View/download PDF

37. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease.

Author

Awasthi S, Grass GD, Torres-Roca J, Johnstone PAS, Pow-Sang J, Dhillon J, Park J, Rounbehler RJ, Davicioni E, Hakansson A, Liu Y, Fink AK, DeRenzis A, Creed JH, Poch M, Li R, Manley B, Fernandez D, Naghavi A, Gage K, Lu-Yao G, Katsoulakis E, Burri RJ, Leone A, Ercole CE, Palmer JD, Vapiwala N, Deville C, Rebbeck TR, Dicker AP, Kelly W, and Yamoah K

Subjects
Male, Humans, Prospective Studies, Black or African American genetics, Genetic Testing, Prostatectomy, Prostatic Neoplasms diagnosis, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology
Abstract

Background: Personalized genomic classifiers have transformed the management of prostate cancer (PCa) by identifying the most aggressive subsets of PCa. Nevertheless, the performance of genomic classifiers to risk classify African American men is thus far lacking in a prospective setting., Methods: This is a prospective study of the Decipher genomic classifier for National Comprehensive Cancer Network low- and intermediate-risk PCa. Study-eligible non-African American men were matched to African American men. Diagnostic biopsy specimens were processed to estimate Decipher scores. Samples accrued in NCT02723734, a prospective study, were interrogated to determine the genomic risk of reclassification (GrR) between conventional clinical risk classifiers and the Decipher score., Results: The final analysis included a clinically balanced cohort of 226 patients with complete genomic information (113 African American men and 113 non-African American men). A higher proportion of African American men with National Comprehensive Cancer Network-classified low-risk (18.2%) and favorable intermediate-risk (37.8%) PCa had a higher Decipher score than non-African American men. Self-identified African American men were twice more likely than non-African American men to experience GrR (relative risk [RR] = 2.23, 95% confidence interval [CI] = 1.02 to 4.90; P = .04). In an ancestry-determined race model, we consistently validated a higher risk of reclassification in African American men (RR = 5.26, 95% CI = 1.66 to 16.63; P = .004). Race-stratified analysis of GrR vs non-GrR tumors also revealed molecular differences in these tumor subtypes., Conclusions: Integration of genomic classifiers with clinically based risk classification can help identify the subset of African American men with localized PCa who harbor high genomic risk of early metastatic disease. It is vital to identify and appropriately risk stratify the subset of African American men with aggressive disease who may benefit from more targeted interventions., (Published by Oxford University Press 2022.)

Published
2022
Full Text
View/download PDF

38. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer.

Author

D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, and Shariat SF

Subjects
Adult, Age Factors, Aged, Aged, 80 and over, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Neoplasm Invasiveness, Preoperative Period, Retrospective Studies, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms surgery
Abstract

Purpose: To assess the association of patient age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer (MIBC)., Materials and Methods: We analyzed data from 1105 patients with MIBC. Patients age was evaluated as continuous variable and stratified in quartiles. Pathologic objective response (pOR; ypT0-Ta-Tis-T1N0) and pathologic complete response (pCR; ypT0N0), as well survival outcomes were assessed. We used data of 395 patients from The Cancer Genome Atlas (TCGA) to investigate the prevalence of TCGA molecular subtypes and DNA damage repair (DDR) gene alterations according to patient age., Results: pOR was achieved in 40% of patients. There was no difference in distribution of pOR or pCR between age quartiles. On univariable logistic regression analysis, patient age was not associated with pOR or pCR when evaluated as continuous variables or stratified in quartiles (all p > 0.3). Median follow-up was 18 months (IQR 6-37). On Cox regression and competing risk regression analyses, age was not associated with survival outcomes (all p > 0.05). In the TCGA cohort, patient with age ≤ 60 years has 7% less DDR gene mutations (p = 0.59). We found higher age distribution in patients with luminal (p < 0.001) and luminal infiltrated (p = 0.002) compared to those with luminal papillary subtype., Conclusions: While younger patients may have less mutational tumor burden, our analysis failed to show an association of age with response to preoperative chemotherapy or survival outcomes. Therefore, the use of preoperative chemotherapy should be considered regardless of patient age., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

39. Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay.

Author

Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, Basler JW, Hernandez J, Liss MA, Porter MP, Wright JL, Risk MC, Garzotto M, Efimova O, Barrett L, Berse B, Kemeter MJ, Febbo PG, and Dash A

Subjects
Adult, Aged, Aged, 80 and over, Biopsy, Genetic Markers, Genetic Predisposition to Disease genetics, Humans, Male, Middle Aged, Prospective Studies, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy, Retrospective Studies, Risk Factors, United States, United States Department of Veterans Affairs, Veterans statistics & numerical data, Watchful Waiting statistics & numerical data, Genetic Testing methods, Prostatic Neoplasms diagnosis, Risk Assessment methods, Watchful Waiting methods
Abstract

Background: Active surveillance (AS) has been widely implemented within Veterans Affairs' medical centers (VAMCs) as a standard of care for low-risk prostate cancer (PCa). Patient characteristics such as age, race, and Agent Orange (AO) exposure may influence advisability of AS in veterans. The 17-gene assay may improve risk stratification and management selection., Objectives: To compare management strategies for PCa at 6 VAMCs before and after introduction of the Oncotype DX Genomic Prostate Score (GPS) assay., Study Design: We reviewed records of patients diagnosed with PCa between 2013 and 2014 to identify management patterns in an untested cohort. From 2015 to 2016, these patients received GPS testing in a prospective study. Charts from 6 months post biopsy were reviewed for both cohorts to compare management received in the untested and tested cohorts., Subjects: Men who just received their diagnosis and have National Comprehensive Cancer Network (NCCN) very low-, low-, and select cases of intermediate-risk PCa., Results: Patient characteristics were generally similar in the untested and tested cohorts. AS utilization was 12% higher in the tested cohort compared with the untested cohort. In men younger than 60 years, utilization of AS in tested men was 33% higher than in untested men. AS in tested men was higher across all NCCN risk groups and races, particular in low-risk men (72% vs 90% for untested vs tested, respectively). Tested veterans exposed to AO received less AS than untested veterans. Tested nonexposed veterans received 19% more AS than untested veterans. Median GPS results did not significantly differ as a factor of race or AO exposure., Conclusions: Men who receive GPS testing are more likely to utilize AS within the year post diagnosis, regardless of age, race, and NCCN risk group. Median GPS was similar across racial groups and AO exposure groups, suggesting similar biology across these groups. The GPS assay may be a useful tool to refine risk assessment of PCa and increase rates of AS among clinically and biologically low-risk patients, which is in line with guideline-based care.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results